JUVELOOK vs Rejuran: Evidence—and Where Exosomes Fit

This article preserves the clinical question in a Korean article written by Dr. SangYoul Yun, board-certified dermatologist and Medical Director of Delight Dermatology in Gangnam, Seoul. Read the Korean original on Naver. The evidence wording and commercial hold were rechecked against the cited primary studies and systematic review on 29 July 2026.

The short answer

JUVELOOK and Rejuran are different injectables; a topical product marketed as containing exosomes is not the same kind of treatment. JUVELOOK combines poly-D,L-lactic acid (PDLLA) particles with non-crosslinked hyaluronic acid (HA). Rejuran is a purified polynucleotide (PN) injectable. The exosome evidence most relevant to cosmetic dermatology has generally studied topical adjuncts used with procedures such as fractional laser or microneedling—not a standardized, standalone injectable.

No good evidence establishes one universal winner, age cutoff, duration, session count, or combination protocol. The useful comparison starts with the exact product, treatment route, diagnosed concern, and strength of the evidence—not the category name “skin booster.”

JUVELOOK vs Rejuran vs topical exosome adjunct: comparison table

Three names often grouped together in marketing, but not equivalent in material, route, or evidence

Question	JUVELOOK	Rejuran	Topical exosome adjunct
What is it?	PDLLA particles plus non-crosslinked HA	Purified polynucleotide (PN)	A topical formulation marketed as containing extracellular-vesicle/exosome material
What route does the cited evidence address?	Intradermal injectable	Intradermal injectable	Topical adjunct after a selected procedure; this evidence does not support injection or intravenous administration
Main proposed role	Gradual collagen-related skin-quality change	Skin-quality treatment with reported changes in texture, wrinkles, hydration or elasticity	Possible adjunct to recovery or outcomes after a procedure
Best evidence summary	Small preliminary studies; product and formulation matter	Nine low- or moderate-quality studies involving 219 patients in a 2025 systematic review	Small, heterogeneous adjunct studies; the key acne-scar trial used topical gel after fractional CO₂ laser
What the evidence does not prove	A universal 14–20 month duration, a fixed age group, or a precise nodule rate	That PN and PDRN are interchangeable, or that one schedule works for every area	That every product is equivalent, that injection is supported, or that it works as a standalone treatment

What the JUVELOOK evidence actually shows

JUVELOOK contains PDLLA and non-crosslinked HA. PDLLA is intended to create a gradual tissue response associated with collagen formation, while the HA component contributes to the injectable carrier and early hydration. That mechanism is biologically different from PN.

The most directly relevant published skin-rejuvenation study was preliminary: 16 Asian participants received two or three sessions four weeks apart. Investigators reported improvements in several clinical skin-aging measures and increases in collagen and elastic fibres on limited histology, with no severe adverse events (PMID 37969055). Because it had no untreated or active control group and a small sample, it cannot establish superiority, one ideal schedule, or a universal duration.

JUVELOOK and JUVELOOK Volume should also not be treated as interchangeable labels. Published studies of deeper nasolabial-fold or tear-trough correction may use a different PDLLA-HA formulation, concentration, depth, or endpoint. Evidence for a volumizing formulation cannot automatically be used to promise the same result from a superficial skin-quality protocol.

What the Rejuran and PN evidence actually shows

Rejuran is described in the medical literature as a PN injectable. PN and polydeoxyribonucleotide (PDRN) are related DNA-derived materials, but they are not exact synonyms. PDRN's better-described adenosine A2A-receptor pharmacology should not be copied wholesale onto PN products. The distinction and its limits are explained in our Rejuran PN vs PDRN evidence review.

A 2025 systematic review found nine PN studies involving 219 patients. Several reported improvements in wrinkles, texture, hydration or elasticity, and reported adverse effects were generally mild and transient. However, the studies used different products, facial areas, techniques, schedules and outcomes, and their quality was rated low or moderate (PMID 39645667). The appropriate conclusion is “promising but not standardized,” not a guaranteed four- to six-month result or an age-based rule.

One randomized, double-blind, split-face trial compared three PN sessions with non-crosslinked HA in 27 participants' under-eye areas. Overall visual and global-improvement scores were not significantly different, although some elasticity, hydration, roughness and pore measurements favoured PN; no serious adverse events were reported in that small study (PMID 32248707). This is useful but narrow evidence, not proof for every Rejuran formulation or facial concern.

Where topical exosome products fit—and where they do not

“Exosome” describes extracellular vesicles involved in cell-to-cell signalling; it is not a single standardized cosmetic product. Source cells, isolation, purification, concentration, formulation, storage, sterility and application route can all differ. The studies summarized here do not verify what this clinic offers. Product availability and every clinic route remain unpublished until the exact product, authorization, handling, consent and route-specific evidence are confirmed.

The frequently cited acne-scar trial enrolled 25 participants. Everyone received three fractional CO₂ laser sessions; one side then received human adipose-tissue stem-cell-derived exosome gel and the other side a control gel. At 12 weeks, the exosome-treated sides had a greater reduction in acne-scar scores and shorter erythema downtime (PMID 33073298). This supports further study of that specific topical gel after that specific laser protocol. It does not prove that an injected exosome “skin booster” works, that every topical product is equivalent, or that exosomes alone treat acne scars.

A directly relevant 2026 review of microneedling used with exosome products retained only eight small studies, with sample sizes from 3 to 60, and called for larger studies and longer follow-up before efficacy and safety can be established (PMID 42027180). The U.S. FDA also states that there are currently no FDA-approved exosome products; that U.S. statement does not decide every Korean cosmetic classification, but it is an important warning against treating “exosome” as a standardized approval or efficacy claim (FDA safety notification).

Choose by the diagnosed problem, not by age

• Dryness, fine lines or texture: PN, PDLLA-HA, HA injectables and non-injectable options answer different parts of the problem. Examination determines whether an injectable is justified.
• Enlarged pores or acne scars: scar type and depth matter. RF microneedling, fractional laser, subcision or other scar-directed treatment may be more important than the adjunct placed afterward.
• Redness or reactive skin: diagnose rosacea, dermatitis or active inflammation first. “Sensitive skin” is not an automatic indication for Rejuran or an exosome product.
• Volume loss or substantial laxity: a superficial skin-quality injectable may not address the anatomical problem. Filler, a biostimulator, an energy device, surgery—or no procedure—may be the more honest discussion.

Age alone does not select a product. Two people of the same age can have different anatomy, skin disease, scar patterns, medication histories, recovery constraints and goals.

Does combining treatments work better?

“Different mechanisms” does not automatically mean “proven synergy.” A combination may be reasonable when each component has a separate, defensible indication, but the current evidence does not establish one universal JUVELOOK–Rejuran–exosome sequence. More products can also mean more cost, swelling, bruising, uncertainty and difficulty identifying the cause of a reaction.

A careful plan explains what each component adds, which part is optional, why the order and interval were chosen, and what would change if one component were omitted.

Risks and recovery questions

Injectables can cause pain, redness, swelling, bruising, temporary raised injection marks and infection. Particulate collagen stimulators can also produce delayed papules or nodules; the available evidence does not support quoting one universal JUVELOOK percentage. Serious vascular injury is uncommon but is a safety consideration for facial injection procedures, making anatomy, depth, technique and prompt recognition important.

For PN, published cosmetic studies are too small to rule out uncommon complications. For a topical adjunct used after a device, safety also depends on the product's formulation, handling, sterility and the barrier disruption created by the procedure. Seek prompt clinical review for worsening pain, blanching or dusky colour, spreading redness, pus, fever, visual symptoms, or an unexpected persistent lump.

What to ask before booking in Seoul

1. What is the exact product and formulation? Ask to see the sealed package and lot details.
2. Is it injected or applied topically? Do not let the shared “skin booster” label hide a different route.
3. What diagnosed concern is each component addressing? Ask what would happen if you chose only one part.
4. Which study supports this product, route, facial area and endpoint? Evidence from another formulation should be labelled as indirect.
5. Who performs the injection or device treatment? Ask how anatomy and technique change the plan.
6. What recovery buffer fits my flight or event? A fixed downtime promise is less useful than a product- and technique-specific range.
7. What are the alternatives and itemized costs? “Wait and reassess” should remain an available option.

Frequently asked questions

Which is better, JUVELOOK or Rejuran?

Neither is universally better. They use different materials, and the evidence does not support selecting one by age alone. The decision should match the diagnosed concern, area, formulation, risk and recovery plan.

Is an exosome product the same as a skin-booster injection?

No. The relevant clinical studies often evaluated a topical adjunct after laser or microneedling. That evidence should not be presented as proof for injection, and this page does not state that the clinic offers an exosome product by any route.

Can JUVELOOK and Rejuran be combined?

They can be planned in the same overall course for selected patients, but no universal combination protocol or superiority has been established. Each component needs its own reason.

How long do the results last?

The published studies differ by product, formulation, area, schedule and endpoint. They do not support one universal duration for either category. Ask what evidence supports the estimate given for the exact treatment proposed.

Bottom line: JUVELOOK, Rejuran and topical exosome adjuncts should not be sold as three interchangeable versions of the same treatment. A useful consultation identifies the material, route, evidence, uncertainty and anatomical goal before discussing a package.

Reviewed by

Clinical framework from Dr. SangYoul Yun's Korean article. Evidence scope and the commercial publication hold were reviewed against the cited studies on 29 July 2026. This article gives general information and does not predict an individual result.

Sources

1. Seo SB et al. Skin rejuvenation effect of combined PDLLA and non-crosslinked hyaluronic acid: a preliminary study. J Cosmet Dermatol. 2024. PMID 37969055
2. Lampridou S et al. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. J Cosmet Dermatol. 2025. PMID 39645667
3. Lee YJ et al. Polynucleotide and hyaluronic-acid fillers for periocular rejuvenation: randomized split-face trial. J Dermatolog Treat. 2022. PMID 32248707
4. Kwon HH et al. Human adipose-tissue stem-cell-derived exosome gel after fractional CO₂ laser for acne scars: randomized split-face study. Acta Derm Venereol. 2020. PMID 33073298
5. Dhaliwal NK et al. The Use of Microneedling With Exosomes in Dermatology: A Systematic Review. J Cosmet Dermatol. 2026. PMID 42027180
6. U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. FDA

Medical disclaimer: This article is general education, not a diagnosis or prescription. Product choice, route, procedure suitability and aftercare require an individualized medical assessment.